<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366301</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-000823</org_study_id>
    <secondary_id>Lantus_L_00833</secondary_id>
    <nct_id>NCT00366301</nct_id>
  </id_info>
  <brief_title>The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes</brief_title>
  <official_title>The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study, which is being conducted at 100 centers throughout the United
      States, is to determine whether Lantus, a long-acting insulin injection, either alone or in
      combination with metformin, is effective in reducing C-reactive protein (CRP) in adults with
      type 2 diabetes. CRP is a marker of chronic low-level inflammation, a new risk factor for
      diabetes, heart attack, stroke, and other cardiovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Rationale

      Low-grade systemic inflammation as indicated by elevated levels of C-reactive protein (CRP)
      is often present in patients with type 2 diabetes. Individuals with type 2 diabetes represent
      a vulnerable population in which cardiovascular event rates are high and among whom CRP
      reduction may have the greatest impact. While several classes of oral hypoglycemic agents
      have been shown to lower CRP, data are not available for newer formulations of long-acting
      insulins such as Lantus (insulin glargine injection) and no study has comprehensively
      evaluated the relative merit of insulin-providing versus insulin-sensitizing strategies for
      this purpose.

      Investigational Plan

      This is a multicenter, community-based, randomized 2x2 factorial trial of Lantus and
      metformin among patients with type 2 diabetes treated with either diet or oral monotherapy
      (other than metformin) only who have poor glycemic control and elevated CRP. The primary
      endpoint is change in CRP. Secondary endpoints include improvement in insulin sensitivity,
      glycemic control, blood lipids, as well as selected inflammatory and prothrombotic markers,
      and adipokine levels.

      Limited data suggest that short-term insulin administration in patients with poorly
      controlled type 2 diabetes may lower CRP, but the benefit of CRP reduction that is unique to
      insulin therapy and independent of glycemic control per se remains uncertain. The
      insulin-sensitizing agent metformin, a mainstay of anti-diabetic therapy, has been shown to
      reduce macrovascular complications among patients with type 2 diabetes and, in some but not
      all randomized clinical trials, also has a modest CRP-lowering effect. This study is designed
      to assess whether the use of Lantus either alone or in combination with metformin lowers CRP
      over a 14-week treatment period.

      Eligible men and women age 18 to 79 years with early diabetes on diet only or oral
      monotherapy with baseline HbA1c 7.0-10% and CRP greater than or equal to 2.0 mg/l will be
      randomized in a 2X2 factorial fashion as follows. First, participants will be assigned at
      random to open-label Lantus or no insulin. Then, within these two categories, subjects will
      be assigned at random to metformin or placebo. Thus, the four resultant treatment groups are
      Lantus injection and placebo pill, Lantus injection and metformin pill, metformin pill alone,
      and placebo pill alone. All patients will receive diet and exercise counseling.

      This study design will permit testing of the overall effect of Lantus as well as the effect
      of combination therapy with metformin for CRP reduction at a targeted level of glycemic
      control (fingerstick fasting blood glucose &lt; 110 mg/dl). All participants will be provided
      with a glucometer for fingerstick glucose testing calibrated to report plasma-referenced
      values.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Reduction in C-reactive Protein (CRP)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine plus placebo pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine plus placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine plus metformin pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Glargine plus metformin pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine injection</intervention_name>
    <description>Once daily for 14 weeks</description>
    <arm_group_label>Insulin Glargine plus placebo pill</arm_group_label>
    <arm_group_label>Insulin Glargine plus metformin pill</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Up to 4 pils per day (2g per day) maximum</description>
    <arm_group_label>Metformin Pill</arm_group_label>
    <arm_group_label>Insulin Glargine plus metformin pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Up to 4 pills per day</description>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_label>Insulin Glargine plus placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 to 79

          -  Type 2 diabetes, treated only by diet or oral drugs other than metformin

          -  HbA1c greater than or equal to 7% and less than or equal to 10%

          -  C-reactive protein greater than or equal to 2 mg/L

        Exclusion Criteria:

          -  Baseline use of metformin or insulin

          -  Type 1 diabetes, history of ketoacidosis or positive anti-GAD antibody

          -  History of congestive heart failure requiring drug therapy

          -  Active liver disease

          -  Kidney impairment

          -  Recent initiation or change in dose of statins, fibric acid derivatives, angiotensin
             receptor blockers, nonsteroidal anti-inflammatory agents, or corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M Ridker, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aruna Das Pradhan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>October 26, 2010</results_first_submitted>
  <results_first_submitted_qc>October 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2010</results_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Aruna Das Pradhan, MD, MPH</name_title>
    <organization>Brigham &amp; Women's Hospital, Boston, Massachusetts 02115</organization>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>insulin</keyword>
  <keyword>insulin injection</keyword>
  <keyword>metformin</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>glycemic control</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred at 73 US office-based practices between October 2006 and December 2008.</recruitment_details>
      <pre_assignment_details>Preenrollment evaluation comprised local laboratory testing of hsCRP,HbA1c, and safety parameters (ALT or AST and creatinine). Eligible participants were enrolled in a 2-week run-in. Ability to self-monitor fingerstick blood glucose and perform insulin injection was determined and evaluation for evidence of marked hyperglycemia was undertaken.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Pill</title>
          <description>Placebo pill</description>
        </group>
        <group group_id="P2">
          <title>Metformin Pill</title>
          <description>Metformin pill</description>
        </group>
        <group group_id="P3">
          <title>Insulin Glargine Plus Placebo Pill</title>
          <description>Insulin glargine plus placebo pill</description>
        </group>
        <group group_id="P4">
          <title>Insulin Glargine Plus Metformin Pill</title>
          <description>Insulin Glargine plus metformin pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Either 6W or 14W CRP Obtained</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Pill</title>
          <description>Placebo pill</description>
        </group>
        <group group_id="B2">
          <title>Metformin Pill</title>
          <description>Metformin pill</description>
        </group>
        <group group_id="B3">
          <title>Insulin Glargine Plus Placebo Pill</title>
          <description>Insulin glargine plus placebo pill</description>
        </group>
        <group group_id="B4">
          <title>Insulin Glargine Plus Metformin Pill</title>
          <description>Insulin Glargine plus metformin pill</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="10.9"/>
                    <measurement group_id="B2" value="53.8" spread="11.5"/>
                    <measurement group_id="B3" value="53.8" spread="11.4"/>
                    <measurement group_id="B4" value="54.0" spread="11.7"/>
                    <measurement group_id="B5" value="53.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Reduction in C-reactive Protein (CRP)</title>
        <time_frame>14 weeks</time_frame>
        <population>As hsCRP was measured at both 6 and 14 weeks, linear mixed models conditioning on baseline hsCRP and adjusting for treatment stratum were constructed with the dependent variable being change in lnCRP. Any subject having either or both 6 week and 14 week measures was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill</title>
            <description>Placebo pill</description>
          </group>
          <group group_id="O2">
            <title>Metformin Pill</title>
            <description>Metformin pill</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine Plus Placebo Pill</title>
            <description>Insulin glargine plus placebo pill</description>
          </group>
          <group group_id="O4">
            <title>Insulin Glargine Plus Metformin Pill</title>
            <description>Insulin Glargine plus metformin pill</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Reduction in C-reactive Protein (CRP)</title>
          <population>As hsCRP was measured at both 6 and 14 weeks, linear mixed models conditioning on baseline hsCRP and adjusting for treatment stratum were constructed with the dependent variable being change in lnCRP. Any subject having either or both 6 week and 14 week measures was included.</population>
          <units>Percent CRP Reduction</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" lower_limit="-27.8" upper_limit="-9.1"/>
                    <measurement group_id="O2" value="-16.1" lower_limit="-25.1" upper_limit="-6.1"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-13.2" upper_limit="8.6"/>
                    <measurement group_id="O4" value="-20.1" lower_limit="-28.8" upper_limit="-10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As hsCRP was measured at both 6 and 14 weeks, linear mixed models conditioning on baseline hsCRP and adjusting for treatment stratum were constructed with the dependent variable being change in lnCRP. The means at each time point were estimated from a repeated-measures model incorporating all 3 time points. The interventions were assessed by fitting terms corresponding to study drug and treatment arm assignment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted models included terms for baseline HbA1c and weight and change in weight at each time point.</method_desc>
            <param_type>Percent Change in Log CRP</param_type>
            <param_value>20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <desc>Occurrence of marked hypoglycemia, weight gain, and other adverse events were collected at each of 6 visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Pill</title>
          <description>Placebo pill</description>
        </group>
        <group group_id="E2">
          <title>Metformin Pill</title>
          <description>Metformin pill</description>
        </group>
        <group group_id="E3">
          <title>Insulin Glargine Plus Placebo Pill</title>
          <description>Insulin glargine plus placebo pill</description>
        </group>
        <group group_id="E4">
          <title>Insulin Glargine Plus Metformin Pill</title>
          <description>Insulin Glargine plus metformin pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Tachycardia Requiring Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chest Pain Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia Requiring Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Diarrhea Requiring Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sepsis Hospitazation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Traumatic Injury/Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis Requiring Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <description>Subjects were queried at each study visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperglycemia: Confirmed Fasting Glucose &gt;= 250 mg/dl</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperglycemia: Any Self-Monitor Blood Glucose &gt;= 400 mg/dl</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Weight Gain &gt;= 5% of Baseline</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="126"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Adverse Event (e.g. diarrhea not requiring hospitalization)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aruna Pradhan</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-8777</phone>
      <email>apradhan@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

